undamentalytics Newsletter
Sign in

Viking Therapeutics, Inc. cash flow statement

In fiscal 2025, Viking Therapeutics, Inc.'s operations generated −$279m of cash.

Cash flow statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2014Dec 20142015Dec 20152016Dec 20162017Dec 20172018Dec 20182019Dec 20192020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMSept 2026
Cash from operations−2−9−11−15−19−25−22−48−48−73−88−279−463
Stock-based pay03213466917304148
Share buybacks000—————7————
Shares issued—251222297————————

Free cash flow is cash from operations minus capital spending. Free cash flow after stock pay also subtracts stock-based compensation, a real cost to shareholders that the cash flow statement adds back. Dividends, buybacks and shares issued are cash amounts for the period.

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Viking Therapeutics, Inc.'s SEC filings (10-K and 10-Q), retrieved October 30, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Viking Therapeutics, Inc.